Neill was diagnosed with a rare form of cancer called angioimmunoblastic T-cell lymphoma in 2022.

A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal.

Lymphoma is a cancer of lymphocyte cells. Lymphocytes are one of our white blood cells and they play an important role in helping our body to fight off infection. They are present in lymph fluid which circulates around the body via a network of lymph nodes ...

Lymphoma is a type of blood cancer that targets the lymphatic system. This type of cancer impacts the cells that are a part of one's immune system, according to the American Cancer Society. There are several different kinds of lymphoma, including Hodgkin ...

Angioimmunoblastic T-cell lymphoma frequently presents with systemic and immune-mediated features that overlap with autoimmune/infectious syndromes, necessitating tissue diagnosis and comprehensive staging with functional imaging. Ann Arbor staging defines ...

Translocations are chromosomal "cut and paste" errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but aggressive subtype diagnosed in about one in every ...

Cancer can affect all parts of the body, including the blood. Leukemia and lymphoma are types of blood cancer. It’s estimated that in 2016 in the United States, approximately 60,000 people will be diagnosed with leukemia and 80,000 people will be ...

Real-world data presented at the American Society of Clinical Oncology (ASCO) annual meeting reinforced the effectiveness and safety of bispecific antibodies for relapsed or refractory follicular lymphoma, including in patients with high-risk disease features.

A phone call on April 27 changed everything. Natalia Paragoni, influencer and partner of Andrea Zelletta, was eight months pregnant when she was diagnosed with Hodgkin's lymphoma a tumor of

De novo cancer may double the risk for long-term mortality among solid organ transplantation recipients, a population-based study shows.